Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors (MYTHIC)

16. november 2026 oppdatert av: Debiopharm International SA

Fase 1-studie av sikkerhet, farmakokinetikk, farmakodynamikk og foreløpig klinisk aktivitet av RP-6306 alene eller i kombinasjon med RP-3500 hos pasienter med avanserte solide svulster

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Phase 1/1b, multi-center, open-label, dose-escalation study to:

  • Evaluate the safety profile and MTD of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib when administered orally to establish the recommended Phase 2 dose and schedule
  • Characterize the PK and pharmacodynamics of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib
  • Assess preliminary anti-tumor activity associated with lunresertib alone and in combination with RP-3500 or in combination with zedoresertib

This study was previously posted by Repare Therapeutics. In September 2025, sponsorship of the trial was transferred to Debiopharm International S.A

Expanded Access Status: There is no expanded access program available for the investigational products in this study at this time.

Studietype

Intervensjonell

Registrering (Antatt)

464

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • Fullført
        • #2002, The Hospital for Sick Children
      • Toronto, Ontario, Canada, M5G 2C1
        • Rekruttering
        • #2001, Princess Margaret Cancer Centre
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Fullført
        • #2003, The Research Institute of the McGill University Health Centre
      • Copenhagen, Danmark
        • Rekruttering
        • #4001, Rigshospitalet - Blegdamsvej
    • California
      • Los Angeles, California, Forente stater, 90095
        • Fullført
        • # 1019, UCLA, Westwood Cancer Center
      • San Francisco, California, Forente stater, 94158
        • Rekruttering
        • #1025, University of California San Francisco
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06520
        • Rekruttering
        • #1012, Yale
    • Florida
      • Jacksonville, Florida, Forente stater, 32224
        • Rekruttering
        • #1017, Mayo Clinic
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • #1002, Dana Farber Cancer Institute
    • Michigan
      • Grand Rapids, Michigan, Forente stater, 49503
        • Rekruttering
        • #1023, START Midwest
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55902
        • Rekruttering
        • #1016, Mayo Clinic
    • Missouri
      • St Louis, Missouri, Forente stater, 63130
        • Rekruttering
        • #1011, Washington University
    • New York
      • New Hyde Park, New York, Forente stater, 11042
        • Rekruttering
        • #1032, Northwell Health Cancer Institute
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • #1004, Memorial Sloan Kettering Cancer Institute
      • New York, New York, Forente stater, 10032
        • Fullført
        • #1008, Columbia University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Fullført
        • #1010, University of Pennsylvania
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02903
        • Rekruttering
        • #1007, Rhode Island Hospital
      • Providence, Rhode Island, Forente stater, 02903
        • Rekruttering
        • #1030, Women & Infants Hospital of Rhode Island
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • #1001, The University of Texas M.D. Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • #1013, The University of Utah
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • Rekruttering
        • #1027, University of Virginia
      • Madrid, Spania, 28027
        • Har ikke rekruttert ennå
        • Clinica Universidad de Navarra
      • Madrid, Spania, 28050
        • Rekruttering
        • Hospital Universitario HM Sanchinarro
      • Madrid, Spania, 28040
        • Rekruttering
        • START Madrid. Hospital Fundación Jimenez Diaz
      • Navarra, Spania, 31008
        • Har ikke rekruttert ennå
        • Clinica Universidad de Navarra
      • London, Storbritannia, W1G 6AD
        • Rekruttering
        • #3003, Sarah Cannon Research Institute

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female and ≥12 years-of-age at the time of informed consent.
  • Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age.
  • Locally advanced or metastatic resistant or refractory solid tumors.
  • Patients <18 years of age must weigh at least 40 kg.
  • Submission of available tumor tissue at screening or willingness to have a biopsy performed if safe and feasible
  • Next generation sequencing (NGS) report obtained in a CLIA-certified or equivalent laboratory demonstrating eligible tumor biomarker.
  • CCNE1 amplification (non-equivocal) as determined by either a tumor or plasma NGS test, or FISH
  • FBXW7 deleterious mutations identified by either a tumor or plasma NGS test
  • PPP2R1A deleterious mutations identified by either a tumor or plasma NGS test
  • Measurable disease as per RECIST v1.1. For certain modules, patients with prostate cancer or ovarian cancer that have non-measurable disease but have elevated tumor markers (PSA or CA-125, respectively) can also be eligible
  • Ability to swallow and retain oral medications.
  • Acceptable hematologic and organ function at screening.
  • Negative pregnancy test (serum) for women of childbearing potential (WOCBP) at Screening.
  • Resolution of all toxicities of prior therapy or surgical procedures.
  • Any prior radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment.

Exclusion Criteria:

  • Chemotherapy or small molecule antineoplastic agent given within 21 days or <5 half-lives, whichever is shorter, prior to first dose of study drug.
  • History or current condition, therapy, or laboratory abnormality that might confound the study results or interfere with the patient's participation for the full duration of the study treatment.
  • Patients who are pregnant or breastfeeding.
  • Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the participating patient's safety.
  • Major surgery within 4 weeks prior to first dose of lunresertib.
  • Uncontrolled, symptomatic brain metastases.
  • Uncontrolled hypertension.
  • Certain prior anti-cancer therapy
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 1: Lunresertib Single-Agent, Dose Escalation and Food-effect Study

Patients receive lunresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.

Oral PKMYT1 Inhibitor

Eksperimentell: Phase 1: Lunresertib in combination with RP-3500, Dose Escalation Study

Patients receive lunresertib with RP-3500 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.

Oral PKMYT1 Inhibitor

Oral ATR Inhibitor

Eksperimentell: Phase 1: Lunresertib in combination with Zedoresertib, Dose Escalation Study

Patients receive lunresertib with zedoresertib orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.

Oral PKMYT1 Inhibitor

Oral WEE1 Inhibitor

Andre navn:
  • Debio 0123

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and Tolerability of lunresertib either in monotherapy or in combination with RP-3500 or with Zedoresertib in patients with eligible advanced solid tumors
Tidsramme: Up to 90 days after last administration of study intervention

Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign measurements

Up to 90 days after last administration of study intervention
To define the MTD of lunresertib monotherapy, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Tidsramme: Up to 90 days after last administration of study intervention

Assessed by the incidence of Dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data

Up to 90 days after last administration of study intervention
To define the MTD of lunresertib in combination with RP-3500 or in combination with Zedoresertib, and determine a recommended Phase 2 dose (RP2D) and preferred schedule
Tidsramme: Up to 90 days after last administration of study intervention

Assessed by the incidence of dose-limiting toxicities (DLTs) and the incidence and severity of cumulative safety data

Up to 90 days after last administration of study intervention
The relative bioavailability of lunresertib capsule formulation as compared to lunresertib tablet formulation in the fasted state
Tidsramme: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition

Assessed by the plasma concentrations of lunresertib with calculation of pharmacokinetic (PK) parameters including maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) , for both formulations in the fasted state.

Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
The effect of food on the PK of tablet formulation of lunresertib when administered in fed conditions compared to administration under fasted conditions
Tidsramme: Time 0 (time of dosing) to 72 hours post-dose for each treatment condition

Assessed by the plasma concentrations of lunresertib with calculation of the ratio of PK parameters (e.g., Cmax and AUC) between the tablet formulation under fasted and fed state.

Time 0 (time of dosing) to 72 hours post-dose for each treatment condition
To assess the safety and tolerability of lunresertib tablets in combination with RP-3500, confirm the MTD of lunresertib tablets in combination with RP-3500, and determine a RP2D and preferred schedule
Tidsramme: Up to 90 days after last administration of study intervention

Assessed by DLTs, TEAEs, safety laboratory assessments, the incidence of DLTs and the incidence and severity of cumulative safety data

Up to 90 days after last administration of study intervention

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The plasma concentrations of lunresertib monotherapy (capsule formulation) in the fasted and fed states
Tidsramme: Up to 90 days after last administration of study intervention

Assessed by the plasma concentrations of lunresertib with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate

Up to 90 days after last administration of study intervention
To assess the relationship between pharmacodynamic biomarkers and PK of lunresertib at different dose levels and/or schedules
Tidsramme: Up to 90 days after last administration of study intervention

Assessed by evaluation of biomarkers in pre- and on-treatment biopsies, and circulating tumor DNA (ctDNA) dynamics during treatment

Up to 90 days after last administration of study intervention
The plasma concentrations of lunresertib and RP-3500 when dosed in combination
Tidsramme: Up to 90 days after last administration of study intervention

Assessed by the plasma concentrations of lunresertib and RP-3500 with calculation of maximum observed plasma concentration (Cmax), time to maximum observed plasma concentration (Tmax), minimum observed plasma concentration (Cmin), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and other parameters as appropriate for each analyte

Up to 90 days after last administration of study intervention
To assess preliminary anti-tumor activity achieved with lunresertib monotherapy, lunresertib in combination with RP-3500 or lunresertib in combination with Zedoresertib
Tidsramme: Through Study Completion, an average of 1 year

Measured by best percent change in tumor size from baseline, objective response rate (ORR), overall response rate, tumor marker response, duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS).

Through Study Completion, an average of 1 year
To assess the safety and anti-tumor effects of lunresertib capsule + RP-3500
Tidsramme: Through Study Completion, an average of 1 year

As measure by TEAEs, safety laboratory assessments, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS

Through Study Completion, an average of 1 year
To further characterize the PK of lunresertib tablets and assess preliminary anti-tumor
Tidsramme: Through Study Completion, an average of 1 year

Measured by Plasma concentrations of lunresertib with calculation of Cmax, Tmax, AUC, elimination t1/2, and other PK parameters as appropriate, Best percent change in tumor size from baseline, ORR, overall response rate, DOR, CBR, tumor marker response, PFS

Through Study Completion, an average of 1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. april 2021

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

9. april 2021

Først innsendt som oppfylte QC-kriteriene

19. april 2021

Først lagt ut (Faktiske)

22. april 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • Debio 0123-106
  • RP-6306-01 (Annen identifikator: Repare Therapeutics)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .